Comparison
Bromantane vs Noopept
Side-by-side of Bromantane and Noopept. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Bromantane
Bromantane, the Russian nootropic sold as Ladasten (ADK-709), acts on dopamine to cut fatigue and anxiety without classical stimulant rebound.
Noopept
Noopept cognitive enhancer profile: 10 to 30 mg dosage, dipeptide nootropic mechanism, memory effects, and how it compares to piracetam.
Effects at a glance
Bromantane
- •Russian RCT base (Voznesenskaya 2010, n=728) supports 50 mg daily for asthenia and fatigue over 4 weeks
- •Atypical actogenic mechanism: induces tyrosine hydroxylase rather than direct monoamine release
- •Subjective profile is anxiolytic plus mildly motivating, distinct from classical stimulants
- •Long half-life of around 11 hours supports once-daily morning dosing
- •WADA-banned since 1996; relevant for tested athletes
- •Western evidence base is thin; most published trials are Russian-language and not independently replicated
Noopept
- •Russian dipeptide nootropic developed in the 1990s, registered in Russia 2002 for cognitive impairment
- •Roughly 1,000-fold higher per-mg potency than piracetam; therapeutic dose 10 to 30 mg/day
- •Active metabolite cycloprolylglycine modulates AMPA receptors and increases NGF and BDNF in rodent hippocampus
- •Russian RCTs in stroke recovery and vascular cognitive impairment show modest improvements over 4 to 8 weeks
- •Western evidence base is essentially absent; healthy-adult enhancement trials have not been published
- •Unscheduled in the US but not approved for human consumption; UK is prescription-only since 2014
Side-by-side
| Attribute | Bromantane | Noopept |
|---|---|---|
| Category | nootropic | nootropic |
| Also known as | Ladasten, ADK-709, N-(4-bromophenyl)adamantan-2-amine | GVS-111, N-phenylacetyl-L-prolylglycine ethyl ester, Omberacetam |
| Half-life (hr) ↗ | 11 | 0.7 |
| Typical dose (mg) ↗ | 75 | 20 |
| Dosing frequency | daily, morning | 2 to 3 times daily, last dose before mid-afternoon |
| Routes | oral | oral, sublingual |
| Onset (hr) | 3 | 0.5 |
| Peak (hr) | 168 | 1 |
| Molecular weight | 280.21 | 318.37 |
| Molecular formula | C16H20BrN | C17H22N2O4 |
| Mechanism | Indirect dopaminergic and serotonergic actogenic activity via induction of tyrosine hydroxylase and selective increases in serotonin synthesis in hippocampus and hypothalamus. | Hydrolyzed to active metabolite cycloprolylglycine; AMPA receptor modulation, BDNF and NGF upregulation, antioxidant and antiexcitotoxic effects. |
| Legal status | Approved in Russia (Ladasten); unscheduled and unapproved in US, EU, UK | Approved in Russia and CIS states; prescription-only in UK; unscheduled and unapproved in US, EU varies |
| WADA status | banned | unknown |
| DEA / Rx | Not scheduled in the US | Not scheduled in the US |
| Pregnancy | Not recommended | Not recommended |
| CAS | 87913-26-6 | 157115-85-0 |
| PubChem CID | 9576456 | 183503 |
| Wikidata | Q4093816 | Q4321022 |
Safety profile
Bromantane
Common side effects
- mild GI upset
- headache
- skin rash
- occasional insomnia at higher doses
Contraindications
- pregnancy
- lactation
- severe hepatic impairment
- severe renal impairment
- pediatric use
Interactions
- MAOIs: theoretical additive dopaminergic and serotonergic activity(major)
- levodopa and dopamine agonists: additive dopaminergic activity(moderate)
- SSRIs and other serotonergic drugs: theoretical serotonergic additivity(moderate)
- classical stimulants: theoretical additive activity, undocumented(moderate)
Noopept
Common side effects
- headache
- irritability
- sleep disturbance with late-day dosing
- occasional blood pressure elevation
Contraindications
- pregnancy
- lactation
- pediatric use
- severe hepatic impairment
- severe renal impairment
Interactions
- memantine and other glutamatergic agents: theoretical AMPA-pathway interaction(minor)
- antidepressants: theoretical effect via BDNF axis, undocumented(minor)
- antihypertensives: occasional blood pressure elevation may require monitoring(minor)
Which Should You Take?
Noopept comes out ahead for most readers on the criteria we weight: 3 catalogued goals, controlled substance, oral dosing, with a Tier-B outcome catalogued. Bromantane is the right call when one of the conditionals below applies.
- → If your priority is fatigue resistance, pick Bromantane.
- → If your priority is memory, pick Noopept.
- → If your priority is focus or working memory, pick Noopept.
Edge case: Half-lives differ materially (Bromantane ~11 hr vs Noopept ~0.7 hr). Bromantane reaches steady state faster; Noopept is easier to dial in if tolerability is uncertain.
Default choice: Noopept. Wider use case, and broader goal coverage. Reach for Bromantane only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Bromantane and Noopept?
Bromantane and Noopept differ in category (nootropic vs nootropic), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Bromantane or Noopept?
Bromantane half-life is 11 hours; Noopept half-life is 0.7 hours.
Can you stack Bromantane with Noopept?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper